Publications by authors named "Hua-Jian Yu"

Objective: Hepatocellular carcinoma (HCC) has high intratumoral heterogeneity, which contributes to therapeutic resistance and tumour recurrence. We previously identified Prominin-1 (PROM1)/CD133 as an important liver cancer stem cell (CSC) marker in human HCC. The aim of this study was to investigate the heterogeneity and properties of Prom1+ cells in HCC in intact mouse models.

View Article and Find Full Text PDF

(Ca Eu )WO (x = 0-21 mol%) phosphors were prepared using the classical solid-state reaction method. The influence of Eu ion doping on lattice structure was observed using powder X-ray diffraction and Fourier transform infrared spectroscopy. Furthermore, under this influence, the luminescence properties of all samples were analyzed.

View Article and Find Full Text PDF

Solid evidence shows that tumor-initiating cells (T-ICs) are the root of tumor relapse and drug resistance, which lead to a poor prognosis in patients with hepatocellular carcinoma (HCC). Through an in vitro liver T-IC enrichment approach, we identified nuclear factor (erythroid-derived 2)-like 2 (NRF2) as a transcription regulator that is significantly activated in enriched liver T-IC populations. In human HCCs, NRF2 was found to be overexpressed, which was associated with poor patient survival.

View Article and Find Full Text PDF

Dy -doped Y Al O phosphors were prepared at a relatively low temperature using molten salt synthesis. The phase of the prepared Dy -doped Y Al O phosphors was confirmed using X-ray powder diffraction. Results indicated that Dy doping did not change the Y Al O phase.

View Article and Find Full Text PDF

Tb CeGdAlO phosphors were synthesized through solid-state reactions. The influence of Gd on the luminescence was investigated. Under the excitation at 460 nm, TbCeAlO shows the characteristic emission band of Ce with a peak wavelength at about 554 nm.

View Article and Find Full Text PDF

Objectives: Major adjuvant therapies (ATs) for resected hepatocellular carcinoma (HCC) include chemotherapy, internal radiation therapy (IRT), interferon therapy (IFNT) and immunotherapy but the optimum regimen remains inconclusive. We aim to compare these therapies in terms of patient survival and recurrence rates.

Methods: We searched PubMed, EMBASE and Cochrane library databases for randomized trials comparing the above four therapies until 31 March 2014.

View Article and Find Full Text PDF